Ifmthera
Cambridge, US · Founded 2015 · 11 employees on LinkedIn · 2 known investors
Find your way into Ifmthera
IFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer. The company operates through independently financed R&D subsidiaries, each advancing programs aimed at key control nodes of innate immunity such as NLRP3 and cGAS/STING.
Founders & leadership
Ifmthera was founded in 2015 by Gary D. Glick.
GD
HM
H. Martin SeidelinChief Executive Officer
Board
JF
Investors · 2
Reported raises · per SEC filings
Form D private placements$17.1M disclosed across 1 round · 2016
▶$17.1MraisedJun 2016 · 4 investors · BiotechnologyRule 506(b)
▶$17.1MraisedJun 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary GlickExecutive Officer, Director
- Jean-Francois FormelaDirector
- Amount sold
- $17.1M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Ifmthera do?
- IFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer. The company operates through independently financed R&D subsidiaries, each advancing programs aimed at key control nodes of innate immunity such as NLRP3 and cGAS/STING.
- Who founded Ifmthera?
- Ifmthera was founded by Gary D. Glick in 2015.
- Who are Ifmthera's investors?
- Ifmthera's investors include Atlas Venture, Abingworth.
- How much funding has Ifmthera raised?
- Ifmthera has disclosed $17.1M raised across 1 round.
- Where is Ifmthera headquartered?
- Ifmthera is headquartered in Cambridge, US.